Meeting News CoverageVideo

VIDEO: Drop to treat presbyopia in phase 2 trials

ATLANTA – Liquid Vision from Presbyopia Therapies is being investigated in phase 2 clinical trials as a topical, reversible, short-term treatment for presbyopia, reported Terry Kim, MD, here at SECO

Different from pilocarpine, the drop acts only on the sphincter muscle, not the ciliary muscle, thereby creating miosis without accommodative effect. 

Some patients have shown improvement of up to six lines of near vision, with good distance vision, he said.

ATLANTA – Liquid Vision from Presbyopia Therapies is being investigated in phase 2 clinical trials as a topical, reversible, short-term treatment for presbyopia, reported Terry Kim, MD, here at SECO

Different from pilocarpine, the drop acts only on the sphincter muscle, not the ciliary muscle, thereby creating miosis without accommodative effect. 

Some patients have shown improvement of up to six lines of near vision, with good distance vision, he said.

    See more from SECO